A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Melanoma|Renal Cell Carcinoma|Non Small Cell Lung Cancer|Urothelial Carcinoma|Triple Negative Breast Cancer|HR+/HER2- Breast Cancer|Gastric Cancer
Interventions: DRUG: Dose Escalation Doublet: Combination of NKTR-214 + nivolumab|DRUG: Dose Expansion Doublet: Combination of NKTR-214 + nivolumab|DRUG: Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|DRUG: Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Sponsor: Nektar Therapeutics
Collaborators: Bristol-Myers Squibb